journal article·2018-02Open access

Chemotherapeutic Drug Based Metal–Organic Particles for Microvesicle‐Mediated Deep Penetration and Programmable pH/NIR/Hypoxia Activated Cancer Photochemotherapy

Da Zhang, Ming Wu, Zhixiong Cai, Naishun Liao, Kun Ke, Hongzhi Liu, Ming Li, Gang Liu, Huanghao Yang, Xiaolong Liu, Jingfeng Liu

Advanced Science· Volume 5· Issue 2

Abstract

Abstract A novel metal–organic particle (MOP) based nanodrug formed by mild self‐assembly of chemotherapeutic drugs, including banoxantrone and doxorubicin, through Cu(II)‐mediated coordination effects, is reported. In this nanodrug, Cu(II) acts as a bridge to join AQ4N and DOX, and then, self‐assembly of [‐AQ4N‐Cu(II)‐(DOX) 2 ‐Cu(II)‐] n complexes forms nanosized MOPs (referred to as ADMOPs) through multiple interactions including host–metal–guest coordination, hydrophobic interactions, π‐stacking, and van der Waals force. The ADMOPs reported here have several important features over conventional drugs, including tumor microenvironment pH‐sensitive drug release that can be tracked by “turning on” the fluorescence of AQ4N or DOX through proton competition with Cu(II) to break the coordination bonds and much deeper penetration into solid tumors via microvesicle‐mediated intercellular transfer. Most strikingly, the ADMOPs can serve as stimuli‐responsive nanocarriers to efficiently load the photosensitizer phthalocyanine due to their inherent highly porous characteristics. Thus, the ADMOPs significantly enhance the chemotherapeutic efficacy by “on‐demand” photodynamic therapy, which further induces a hypoxic environment that enhances the reduction of AQ4N to systematically increase the therapeutic efficiency. Taken together, the designed ADMOPs composed of chemotherapeutic drugs may serve as a potential programmable controlled synergistic agent for cancer therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Metal-Organic Frameworks: Synthesis and Applications · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou 350025 P. R. China

The Liver Center of Fujian Province Fujian Medical University Fuzhou 350025 P. R. China

Center for Molecular Imaging and Translational Medicine Xiamen University Xiamen 361005 P. R. China

The Key Lab of Analysis and Detection Technology for Food Safety of the MOE Fujian Provincial Key Laboratory of Analysis and Detection Technology for Food Safety College of Chemistry Fuzhou University Fuzhou 350002 P. R. China

Liver Disease Center The First Affiliated Hospital of Fujian Medical University Fuzhou 350005 P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Fujian Province

References (39)

Show source-provided references
1. 10.1038/nmat377610.1038/nmat3776 ↗
2. 10.1016/j.jconrel.2007.12.01710.1016/j.jconrel.2007.12.017 ↗
3. 10.1002/ange.20050127010.1002/ange.200501270 ↗
4. 10.1002/adma.20120174210.1002/adma.201201742 ↗
5. 10.1039/c2cs35091b10.1039/c2cs35091b ↗
6. 10.1016/j.jconrel.2009.01.00910.1016/j.jconrel.2009.01.009 ↗
7. 10.1002/anie.20050181910.1002/anie.200501819 ↗
8. 10.1016/j.addr.2008.03.01210.1016/j.addr.2008.03.012 ↗
9. 10.1039/C5CS00798D10.1039/C5CS00798D ↗
10. 10.1002/anie.20100004810.1002/anie.201000048 ↗
11. 10.1002/anie.20070393410.1002/anie.200703934 ↗
12. 10.1002/ange.20060516310.1002/ange.200605163 ↗
13. 10.1016/j.catcom.2012.07.01710.1016/j.catcom.2012.07.017 ↗
14. 10.1039/c3dt33000a10.1039/c3dt33000a ↗
15. 10.1021/acsnano.5b0788210.1021/acsnano.5b07882 ↗
16. 10.1038/nmat260810.1038/nmat2608 ↗
17. 10.1021/acs.chemrev.5b0012510.1021/acs.chemrev.5b00125 ↗
18. 10.1016/S0020-1693(00)87099-110.1016/S0020-1693(00)87099-1 ↗
19. 10.1007/BF0068623210.1007/BF00686232 ↗
20. 10.1158/0008-5472.CAN-08-067610.1158/0008-5472.CAN-08-0676 ↗
21. 10.1016/j.addr.2016.04.00110.1016/j.addr.2016.04.001 ↗
22. 10.1016/j.jconrel.2012.06.00210.1016/j.jconrel.2012.06.002 ↗
23. 10.1016/0016-7061(82)90030-110.1016/0016-7061(82)90030-1 ↗
24. 10.1002/anie.20150974410.1002/anie.201509744 ↗
25. 10.1002/chem.20100300510.1002/chem.201003005 ↗
26. 10.1002/anie.20110853010.1002/anie.201108530 ↗
27. 10.7150/thno.1709910.7150/thno.17099 ↗
28. 10.1158/1078-0432.CCR-07-402010.1158/1078-0432.CCR-07-4020 ↗
29. 10.1080/03602532.2016.118893910.1080/03602532.2016.1188939 ↗
30. 10.1021/nl504749410.1021/nl5047494 ↗
31. 10.1016/S0305-7372(03)00106-310.1016/S0305-7372(03)00106-3 ↗
32. 10.1021/cr400135x10.1021/cr400135x ↗
33. 10.1021/acsnano.6b0752510.1021/acsnano.6b07525 ↗
34. Zhang D. · Adv. Sci. · 2017 · 4 · 4
35. 10.1039/C5TB01827G10.1039/C5TB01827G ↗
36. 10.1039/b810409c10.1039/b810409c ↗
37. Cleland J. L. · Cancer Res. · 2005 · 46 · 565
38. 10.1016/j.actbio.2015.08.04910.1016/j.actbio.2015.08.049 ↗
39. 10.1016/S0360-3016(98)00308-310.1016/S0360-3016(98)00308-3 ↗